For research use only. Not for therapeutic Use.
CJJ300 is a transforming growth factor-β (TGF-β) inhibitor with an IC50 of 5.3 µM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex[1].
CJJ300 disturbs protein-protein interactions and prevents TGF-β receptor dimerization (IC50 = 23.6 ± 5.8 µM)[1].
CJJ300 (0-80 µM, 2 h) inhibits the phosphorylation of intracellular mediators in the downstream TGF-β signaling pathways, and suppresses the expression of markers of EMT (epithelial-mesenchymal transition) without cytotoxicity[1].
CJJ300 suppresses TGF-β induced cell migration[1].
| Catalog Number | I043831 |
| CAS Number | 1807631-83-9 |
| Synonyms | N-[[3,5-bis(anilinomethyl)-2,4,6-trimethylphenyl]methyl]aniline |
| Molecular Formula | C30H33N3 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H33N3/c1-22-28(19-31-25-13-7-4-8-14-25)23(2)30(21-33-27-17-11-6-12-18-27)24(3)29(22)20-32-26-15-9-5-10-16-26/h4-18,31-33H,19-21H2,1-3H3 |
| InChIKey | AKBFUAPLAQSPMJ-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=C(C(=C1CNC2=CC=CC=C2)C)CNC3=CC=CC=C3)C)CNC4=CC=CC=C4 |
| Reference | [1]. Han Wu, et al. The development of a novel transforming growth factor-β (TGF-β) inhibitor that disrupts ligand-receptor interactions. Eur J Med Chem. 2020 Mar 1;189:112042. |
